There is a great deal of research going on, regarding the possible cause of=
 CFS, many
of its symptom mechanisms, possible biological markers, treatments, and epi=
demiology.

Dr. Mark Demitrack (U. Michigan) and Dr. Stephen Straus (NIH) and others ar=
e
studying the dysfunction of the hypothalamic-pituitary-adrenal axis as bein=
g a possible
major explanation for CFS. Prof. Robert Suhadolnik (Temple U., Philadelphia=
) is
exploring a possible bio-marker for CFS found in patients' blood. Drs. Hugh=
 Dunstan
and Timothy Roberts (U. Newcastle, Australia) are researching a possible bi=
ological
marker found in urine. Dr. Peter Rowe (Johns Hopkins) is studying the possi=
ble link
between CFS and neurally mediated hypotension. Dr. Anthony Komaroff (Harvar=
d)
and Dr. Dharam Ablashi (Georgetown) are researching the possible roles of H=
HV-6
and EBV (to decipher these abbreviations, see Appendix 3). Drs. Andrew Lloy=
d, Ian
Hickie, Denis Wakefield and Andrew Wilson (Sydney, Australia) aremaking bro=
ad
investigations into many aspect of CFS. Dr. W. John Martin (U. So. Calif.) =
is studying
the "Stealth" virus. Dr. Michael Holmes (U. Otago) is researching another m=
ysterious,
virus-like particle. Drs. Nancy Klimas, Roberto Patarca (of U. Miami) and J=
ay Levy
(UCSF) are investigating immunological abnormalities. Drs. Paul Cheney, Cha=
rles
Lapp and Jay Goldstein are studying various treatments. Drs. Simon Wessely,=
 Michael
Sharpe and other British psychiatrists are exploring the value of cognitive=
 behavior
therapy for CFS. The CDC team led by Drs. Keiji Fukuda and William Reeves a=
re
undertaking prevalence studies in the USA. These are just a few of the more=
 prominent
studies now on-going.